Subscribe to Pharmaceutical Processing Articles

The Lead

Robotics And Medical Marijuana — A Joint Venture

April 21, 2015 | by Meagan Parrish, Editor, Chem.Info | Comments

A startup company that’s found a unique niche in the exploding cannabis industry, Potbotics uses robotic technology to bring medical marijuana use into a new era of high-tech pharma.


Meet the ‘Breaking Bad’ chemist who’s helping make science cool

June 16, 2015 10:48 am | by Meagan Parrish, Editor, Chem.Info | Comments

Dr. Donna Nelson, the former scientific advisor to the hit-show “Breaking Bad” and president-elect of the American Chemical Society talks Hollywood, making meth, and the most urgent issue facing the chemical industry.


Improved detection of pyrogens using the monocyte activation test

June 10, 2015 12:23 pm | by Audrey Borel, PharmD Global Product Manager - Rapid Release Testing Pharma, EMD Millipore; Bodo Holtkamp, Biotest AG, GBU Mikrobiologie; Gabriele Schmitz, Biotest AG, GBU Mikrobiologie; Thomas Hartung, Johns Hopkins University, Center for Alternatives | Comments

When present in pharmaceutical products, pyrogenic substances can prove harmful to humans by causing life threatening fevers. Therefore, testing of pharmaceutical products for pyrogens is critical to ensure patient safety.


Could Maple Syrup Help Cut Use of Antibiotics?

April 17, 2015 3:41 pm | by McGill University | Comments

Syrup extract found to make antibiotics more effective against bacteria.


Why Calibration Needs to Be Made Part of Your APM Strategy

April 8, 2015 11:12 am | by Dan Miklovic, Principal Analyst at LNS Research | Comments

Just as calibration needs to be part of your quality processes, it absolutely needs to be part of your asset performance management (APM) strategy as well.


How Drug Manufacturers Are Impacting The Death Penalty Debate

March 24, 2015 11:22 am | by Meagan Parrish, Editor, Chem.Info | Comments

Polls generally show that the majority of Americans are on board with the death penalty. In October 2014, Gallup reported that 63 percent of Americans were in favor of capital punishment while 33 percent were opposed.


Packaging Entrepreneurs: Legacy Pharmaceutical Packaging

February 20, 2015 10:17 am | by Mike Auerbach, Editor-In-Chief | Comments

Legacy Pharmaceutical Packaging, in St. Louis, Missouri is proud of its entrepreneurial spirit, its operational flexibility and technological expertise, and the breadth of packaging services it offers to its customers in a wide variety of segments of the healthcare industry.


Surviving Pharma’s Uncertain Future

November 20, 2014 10:08 am | by Nathan Furr and Jeff Dyer | Comments

The average cost of developing an approved therapy is around $4.3 billion dollars for companies with three or more approved therapies, according to an analysis completed by Forbes. Imagine, then, our surprise when we discovered a biotechnology company outside of New York City that had developed three approved therapies for an average cost of $0.7 billion dollars – less than 20 percent of the industry average.


Cleanroom Alternatives

November 13, 2014 2:39 pm | by Deepak Mistry and Steven Lynum, Panasonic Healthcare Corporation of North America | Comments

Clean rooms are the standard for cGMP-compliant manufacturing, but the significant time and high costs of manufacturing and maintenance, as well as the lack of mobility, makes them difficult to justify.        


Desiccant Canisters

November 13, 2014 11:37 am | by Mark Florez, Product Manager, Clariant Healthcare Packaging; Randy Caspersen, Vice President, Sales and Marketing, Omega Design Incorporated | Comments

As global demand for bottle-packaged pharmaceuticals grows, incremental upgrades in desiccant canister design yield substantial performance improvements.                 

Cleanroom Energy Efficiency Opportunities

November 6, 2014 2:37 pm | by Al Fosco, Frigel North America | Comments

Like so many industries, pharmaceutical processing is increasingly focused on improving the operational energy efficiency. One challenge that often stands in the way: cleanrooms. In these facilities, energy efficiency understandably takes a back seat to the mission of clean production. As a result, due to FDA-required filtration, high-performance processing machines and other factors, cleanrooms are energy intensive.


Ensuring Dedusting Efficiency by Design

October 31, 2014 3:03 pm | by Nic Michel, General Manager, North America, Pharma Technology Inc. | Comments

Dust has always been an unwanted byproduct of tablet manufacturing. In a perfect world, all powder would flawlessly flow into the hopper, and 100% of the product would emerge as finished tablets. In practice, though, most tablet presses are so inundated with dust after an eight-hour run that they form miniature snow piles on both sides of the feeder, and build-ups of material occur around the takeoff bar and recirculation channel.

The Biosimilars Market

October 31, 2014 11:19 am | by Sarfaraz K. Niazi, Ph.D., Founding Chairman and CEO, Therapeutic Proteins International | Comments

Biosimilars have increasingly become an important and somewhat controversial topic in the healthcare space. Depending on who one speaks to, the opinion on biosimilars changes. However, there are certain truths that all stakeholders should keep in mind.


High Potency, High Reward

October 31, 2014 10:43 am | by Nikita Ernst, Associate Editor | Comments

SAFC, a global supplier of a a wide range of services to the biopharm and pharmaceutical industry, has recently expanded their Madison, Wisconsin facilities to neighboring Verona to rev up their high-potency API manufacturing capabilities.


A Roadmap for Risky Territory

October 15, 2014 3:49 pm | by Jamie T. Hintlian and Ryan Kelly; Ernst & Young | Comments

When it comes to the supply chain, business can be risky. A seminal survey of companies in various industries spanning 62 countries found 85% of respondents have experienced a supply chain disruption over the last 12 months, and 50% of companies had more than one disruption.


Challenges of Scale-up and Commercialization

October 2, 2014 8:25 am | by Christopher Kulp, Executive Vice President, Richman Chemical | Comments

The development of new chemistry-based products for life science markets requires the expertise of talented researchers. However, these same researchers are typically not prepared to solve the many other critical problems necessary for successful commercialization.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.